Earnings Outlook For Y-mAbs Therapeutics
Portfolio Pulse from Benzinga Insights
Y-mAbs Therapeutics (NASDAQ:YMAB) is expected to report a Q4 earnings per share (EPS) of $-0.20 on Thursday, 2024-02-29. Analysts and investors will be looking for the company to beat this estimate and provide positive guidance for the next quarter. The company's past earnings performance shows a pattern of beating EPS estimates, leading to significant share price movements. Shares of Y-mAbs Therapeutics were trading at $16.5 as of February 27, with a 311.45% increase over the last 52-week period.
February 28, 2024 | 6:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Y-mAbs Therapeutics is anticipated to report a Q4 EPS of $-0.20, with a history of beating estimates and positive share price reactions. Shares have significantly appreciated over the past year.
Given Y-mAbs Therapeutics' history of beating EPS estimates and the subsequent positive share price movements, there is a strong likelihood of a positive short-term impact on YMAB's stock price if the trend continues. The anticipation of positive guidance for the next quarter further supports this outlook. The significant appreciation of shares over the last year indicates strong investor confidence, which could be bolstered by another favorable earnings report.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100